Drug Transfer into Milk: Clinical Methods & Issues Patrick J. McNamara University of Kentucky College of Pharmacy College of Pharmacy.

Slides:



Advertisements
Similar presentations
Instant Clinical Pharmacology E.J. Begg
Advertisements

Objectives Discuss the incidence of drug use during pregnancy Review the basic physiology of breast milk development Identify drugs of abuse and their.
HLTH 340 Lecture A4 Toxicokinetic processes: Distribution (part-1)
Dosimetry in Risk Assessment and a bit More Mel Andersen McKim Conference QSAR and Aquatic Toxicology & Risk Assessment June 27-29, 2006.
Advanced Medicinal Chemistry
Modern Tools for Drug Discovery NIMBUS Biotechnology Modern Tools for Drug Discovery
Improving Candidate Quality Through the Prediction of Clinical Outcome.
Lipinski’s rule of five
Module 2 # 2 Pharmacokinetics absorption of drugs drugs can be given iv, im, sc, orally (po) if given parenterally, they should.
Factors Affecting Distribution and Metabolism. Chemical Factors Lipophilicity Structure Ionization Chirality.
Nonlinear pharmacokinetics
Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.
Pharmacokinetics Chapter 4.
Drug-Like Properties: Optimizing Pharmacokinetics and Safety During Drug Discovery Li Di and Edward H. Kerns ACS Short Course.
Practical Pharmacokinetics
Assessing Drug Transfer into Breast Milk Shinya Ito, MD Hospital for Sick Children Toronto, Canada.
Pharmacokinetics Based on the hypothesis that the action of a drug requires presence of a certain concentration in the fluid bathing the target tissue.
Pharmacokinetics (PK): What the body does to the drug? Most drugs: Enter the body by crossing barriers Distributed by the blood to the site of action Biotransform.
Dose Adjustment in Renal and Hepatic Disease
Gokaraju Rangaraju College of Pharmacy
ADME And PHARMACOKINETICS.
LONGITUDNAL SECTION OF KIDNEY KLECOP, Nipani.
CLEARANCE CONCEPTS Text: Applied Biopharm. & PK
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 4 Pharmacokinetics.
JOURNAL CLUB PRESENTATION First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric.
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
Nonlinear Pharmacokinetics
Animal Studies and Human Health Consequences Sorell L. Schwartz, Ph.D. Department of Pharmacology Georgetown University Medical Center.
Drug excretion in milk: Mechanisms of transfer from blood to milk : low molecular weight 1-Diffusion of water soluble low molecular weight substances.
Pharmacology Department
Chapter 4 Pharmacokinetics Copyright © 2011 Delmar, Cengage Learning.
SALIVARY, PROTEIN UNBOUND AND TOTAL PLASMA CONC OF RIFAMPICIN HADIJA H SEMVUA 11/12/2015KCRI_PhD SYMPOSIUM
Renal Excretion of Aristolochic Acid I in the IPK
PHARMACOKINETICS Part 3.
Macitentan – A novel sulfamide
The General Concepts of Pharmacokinetics and Pharmacodynamics
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Noncompartmental Models. Introduction The noncompartmental approach for data analysis does not require any specific compartmental model for the system.
!!!……Molecular Target Concept A gonist Antagonist.
PHARMACOKINETICS Definition: quantitative study of drug absorption, distribution, metabolism, and excretion (ADME), and their mathematical relationship.
DRUG ABSORPTION AND DISTRIBUTION OF DRUG
July 20, 2001 ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Drug Transfer into Breast Milk: Nonclinical and Clinical Methods.
Clearance: basic concept (in vitro) Update OCT 2010.
Pharmacokinetics 2 General Pharmacology M212
415 PHT Plasma Level – Time Curve
Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.
Advantages of Good Drug-like Properties 손한표.
ADME Dr Basma Damiri Toxicology In general, a toxicant should be absorbed in order to have an effect. True or false? Why? False Some toxicants.
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
Lipinski’s rule of five
Chapter 3 PHARMACOKINETICS “What the body does to the drug” Lei Wang
Transportation and Transformation of Xenobiotics
Pharmacokinetics of Vancomycin in Adult Oncology Patients
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Anticonvulsants: Valproic acid
Pharmacokinetics: Drug Distribution and Drug Reservoirs
5 Pharmacodynamics.
Pharmacokinetics: Drug Distribution and Drug Reservoirs
Clinical Pharmacokinetics
Hawler Medical University
SIVANAGESWARARAO MEKALA
Study of Absorption, Excretion and Bioavailability of Drugs in Human (Lab 8) Department of Pharmacology and Toxicology University of Al-Mustansiriyah
Clinical Pharmacokinetics
Introduction to Pharmacology
CHAPTER 4 l. VanValkenburg, RVT, BAS
Section 1, Lecture 2 PHARMACOKINETICS [DRUG]
Clinical Pharmacokinetics
BIOAVAILABILITY.
Pharmacokinetics Asst Prof Dr Inam S. Arif
Section 1. Basic Principles of Pharmacology
Presentation transcript:

Drug Transfer into Milk: Clinical Methods & Issues Patrick J. McNamara University of Kentucky College of Pharmacy College of Pharmacy

Outline Clinical Study Design Issues Clinical Study Design Issues Models Models Active Transport Issues Active Transport Issues Neonatal Exposure Issues Neonatal Exposure Issues Conclusions Conclusions

Neonate Exposure via Milk SS serum conc. SS serum conc. in the neonate Neonatal factors Neonatal factors bioavailability (F), volume of milk consumed (V), nursing interval (  and systemic clearance (Cl) bioavailability (F), volume of milk consumed (V), nursing interval (  and systemic clearance (Cl) Maternal factors Maternal factors bioavailability (F), dosing rate, milk to serum ratio (M/S) and systemic clearance (Cl) bioavailability (F), dosing rate, milk to serum ratio (M/S) and systemic clearance (Cl)

Clinical Study Design Issues Single Time Point vs AUC Approach Single Time Point vs AUC Approach Milk Concentration vs M/S Milk Concentration vs M/S M/S & Neonate Concentrations M/S & Neonate Concentrations

Single Time Point vs AUC Approach Time dependence in M/S (Wilson, 1985) Time dependence in M/S (Wilson, 1985) Hydrochlorothiazide, single dose Hydrochlorothiazide, single dose Nadolol, multiple dose Nadolol, multiple dose Observation of cimetidine in rabbits Observation of cimetidine in rabbits Serum Milk Time (min) Conc (ug/ml) Time (min) M/S AUCm/AUCs

Clinical Study Design Issues Milk Concentration vs M/S Milk Concentration vs M/S Milk concentrations sufficient for exposure est. Milk concentrations sufficient for exposure est. M/S provides greater societal/scientific value M/S provides greater societal/scientific value PK estimate in lactating mother PK estimate in lactating mother Insight into mechanism (passive vs active) Insight into mechanism (passive vs active) Overall modeling of drugs (& chemicals) into milk Overall modeling of drugs (& chemicals) into milk M/S & Neonate Concentrations M/S & Neonate Concentrations Neonatal concentrations - very valuable Neonatal concentrations - very valuable Logistical and ethical issues make these studies difficult to carry out Logistical and ethical issues make these studies difficult to carry out

Models Physiochemical Model Predictions Physiochemical Model Predictions Animal Models Animal Models Cell Culture Models Cell Culture Models

Physiochemical Predictive Models Unbound distribution model [Rasmussen, 1958 & 1959; Sisodia and Stowe, 1964] Unbound distribution model [Rasmussen, 1958 & 1959; Sisodia and Stowe, 1964] pH partition hypothesis pH partition hypothesis Membrane diffusion model [Meakin, 1985] Membrane diffusion model [Meakin, 1985] molecular weight, log P, degree of dissociation molecular weight, log P, degree of dissociation Phase distribution model [Fleishaker, 1987] Phase distribution model [Fleishaker, 1987] physicochemical factors & distribution into milk components physicochemical factors & distribution into milk components log-transformed distribution model [Atkinson and Begg, 1990] log-transformed distribution model [Atkinson and Begg, 1990] stepwise multiple linear regression stepwise multiple linear regression Genetic neural network model [Agatonovic- Kustrin, 2000] Genetic neural network model [Agatonovic- Kustrin, 2000] 60 drug compounds - 61 est. structural features 60 drug compounds - 61 est. structural features

Factors Influencing M/S

Physiochemical Model Prediction Agatonovic-Kustrin, Analytica Chimica Acta 418:181 (2000) Good overall prediction Good overall prediction Obtained with no experimental parameters (e.g., binding, partitioning, etc) Obtained with no experimental parameters (e.g., binding, partitioning, etc) Data analysis still only as good as the data sets used to generate the relationships Data analysis still only as good as the data sets used to generate the relationships

Cell Culture Models Nitrofurantoin Flux across CIT 3 Cells Nitrofurantoin Flux across CIT 3 Cells

Concentration, ug/ml Time, min Animal Models Nitrofurantoin M/S in Rats [Kari, 1997] Nitrofurantoin M/S in Rats [Kari, 1997] Nitrofurantoin in milk and plasma of 10-day lactating rats gavage-fed 50mg/kg nitrofurantoin Nitrofurantoin in milk and plasma of 10-day lactating rats gavage-fed 50mg/kg nitrofurantoin M/P predicted = 0.31 M/P observed = 23.1

M/S Prediction Rabbit M/S Pred M/S Obs Rat NF CM RN AC M/S Pred Human NF CM M/S Pred

Active Transport Issues Clinical evidence Clinical evidence Carriers Carriers Substrate / Drug Database Substrate / Drug Database

Cimetidine in Human Milk Time (h) 1200 mg Serum Milk Time (h) 600 mg Time (h) CONC (ug/ml) 100 mg (Oo, et al, 1995)

ParameterSubject1234MeanSD M/S pred M/S obs Nitrofurantoin in Human Milk (Gerk, et al, 2001)

Transporters C Candidate genes expressed (RT-PCR) in cells isolated from human milk (Ito and McNamara Labs) Protein Expression – Structural studies Functional studies Substrate / Drug Database Substrate / Drug Database

Neonatal Exposure Issues Route of Drug Clearance Route of Drug Clearance Nursing vs Dosing Interval Nursing vs Dosing Interval Mechanism of Toxicity Mechanism of Toxicity Lactation vs Developmental Stage Lactation vs Developmental Stage

Route of Drug Clearance Developmental patterns vary Developmental patterns vary GFR normalized to body weight appears comparable to adult GFR normalized to body weight appears comparable to adult Metabolic pathways vary Metabolic pathways vary CYP-450 and most Phase II reactions are inefficient at birth CYP-450 and most Phase II reactions are inefficient at birth Sulfate conjugation is the exception Sulfate conjugation is the exception

Developmental Expression of Cytochrome P A2 2C 2D6 2E1 3A4 Age, Days % of Adult In Vitro Activity [Vieira, 1996;Treluyer, 1997; Sonnier, 1998]

Nursing vs Dosing Interval Chronic vs Acute Dosing Chronic vs Acute Dosing Generalizations Generalizations Longer t 1/2 longer  Longer t 1/2 longer  Longer  less able to “control” exposure Longer  less able to “control” exposure Time, h Conc Time, h Conc

Neonatal Exposure Higher exposure Higher exposure Higher M/S Higher M/S Lower Cls Lower Cls Maternal Maternal Neonate Neonate Lower First Pass? Lower First Pass?

Conclusions Diffusion accounts for appearance of most drugs in milk Diffusion accounts for appearance of most drugs in milk M/S can be predicted M/S can be predicted unbound, cationic lipophilic drugs favor higher M/S unbound, cationic lipophilic drugs favor higher M/S Transporter gene expression in lactating mammary epithelial cells – limited number of drugs Transporter gene expression in lactating mammary epithelial cells – limited number of drugs Neonate exposure assessment should include: Neonate exposure assessment should include: Maternal clearance: higher clearance less exposure Maternal clearance: higher clearance less exposure Neonatal clearance: lower clearance more exposure Neonatal clearance: lower clearance more exposure Active metabolites should be considered Active metabolites should be considered